TipRanks
Advertisement
Advertisement

ALPMF Stock Latest News

Is ALPMF a Buy, Before Earnings?
Pre-EarningsIs ALPMF a Buy, Before Earnings?
2M ago
Astellas Halts Early KRAS G12D Cancer Trial: What It Means for ALPMF Investors
PremiumCompany Announcements
Astellas Halts Early KRAS G12D Cancer Trial: What It Means for ALPMF Investors
3M ago
ALPMF
Sangamo files for restructuring, plans asset sales to Lilly, Astellas
PremiumThe Fly
Sangamo files for restructuring, plans asset sales to Lilly, Astellas
3M ago
LLY
SGMO
Astellas Wraps Up Real-World Safety Study on Smyraf, Clarifying RA Market Outlook
PremiumCompany Announcements
Astellas Wraps Up Real-World Safety Study on Smyraf, Clarifying RA Market Outlook
4M ago
ALPMF
Pfizer and Astellas Advance New Bladder Cancer Combo in Early Clinical Trial
PremiumCompany Announcements
Pfizer and Astellas Advance New Bladder Cancer Combo in Early Clinical Trial
4M ago
PFE
Astellas Pharma Cuts Director Slate After Outside Director Resigns
PremiumCompany AnnouncementsAstellas Pharma Cuts Director Slate After Outside Director Resigns
4M ago
Astellas Launches Five-Year CSP2026 Plan Targeting Pipeline-Led Record Revenues
Premium
Company Announcements
Astellas Launches Five-Year CSP2026 Plan Targeting Pipeline-Led Record Revenues
4M ago
Astellas Extends Global Performance-Linked Stock Incentives for Executives
Premium
Company Announcements
Astellas Extends Global Performance-Linked Stock Incentives for Executives
5M ago
Astellas Extends Performance-Linked Stock Incentive Plan for Directors in FY2026
PremiumCompany Announcements
Astellas Extends Performance-Linked Stock Incentive Plan for Directors in FY2026
5M ago
Astellas Rated Hold as Xtandi Headwinds Offset Pipeline Potential; Price Target Reiterated at ¥2,200
PremiumRatings
Astellas Rated Hold as Xtandi Headwinds Offset Pipeline Potential; Price Target Reiterated at ¥2,200
5M ago
Astellas Books Major Impairment and Extraordinary Losses in FY2025 Non-Consolidated Results
PremiumCompany Announcements
Astellas Books Major Impairment and Extraordinary Losses in FY2025 Non-Consolidated Results
5M ago
Astellas Pharma Announces New Board Slate and Governance Changes for 2026
PremiumCompany Announcements
Astellas Pharma Announces New Board Slate and Governance Changes for 2026
5M ago
Is ALPMF a Buy, Before Earnings?
PremiumPre-EarningsIs ALPMF a Buy, Before Earnings?
5M ago
Astellas’ Menopause Drug Fezolinetant Hits Key Safety Milestone in Japan
Premium
Company Announcements
Astellas’ Menopause Drug Fezolinetant Hits Key Safety Milestone in Japan
6M ago
ALPMF
Astellas Highlights R&D Strategy While Flagging Market and Development Risks
Premium
Company Announcements
Astellas Highlights R&D Strategy While Flagging Market and Development Risks
6M ago
Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
PremiumCompany Announcements
Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
7M ago
Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
PremiumCompany Announcements
Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
7M ago
Why Is Vir Biotechnology Stock Up Today?
PremiumMarket News
Why Is Vir Biotechnology Stock Up Today?
7M ago
VIR
Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
PremiumCompany Announcements
Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
8M ago
Astellas-Backed Bladder Cancer Trial Nears Key Data Moment After Study Completion
PremiumCompany AnnouncementsAstellas-Backed Bladder Cancer Trial Nears Key Data Moment After Study Completion
8M ago
ALPMF
Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
Premium
Ratings
Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
8M ago
Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand
Premium
Company Announcements
Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand
8M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >